Fortress Biotech, Inc. FBIO Cash Flow

Fortress biotech, inc. (FBIO)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Cash Flows from Operating Activities:
Net loss
-24,068	-32,955	-24,970	-27,480	-16,255	-39,415	-28,587	-35,716	-38,218	-26,018	-36,307	-22,949	-14,562	-21,302	-16,956	-16,389	-16,643	-15,075	-19,855	-6,418	-12,535	-3,713	-4,592	-4,711	-7,370	-	-	-	-
Net loss on discontinued operations
-	-	-	-	-	-7,115	2,643	-6,921	-2,076	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from continuing operations
-	-	-	-	-	-34,633	-31,230	-28,795	-36,142	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7,832	-10,670	-8,858
Reconciliation of net loss to net cash used in operating activities:
Depreciation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	9	6	5	6	-	-	-	-	-	-	-	-
Stock-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,523
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Noncash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-21	188	79	0	40	515	-	-	-	-
Change in fair value of Common Stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Change in fair value of embedded conversion feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Change in fair value of Preferred Stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Depreciation expense
527	486	476	457	481	500	400	304	196	-93	276	269	274	-	-	-	-	-	-	-	-	-	-	-	5	-	4	4	3
Amortization expense of intangible asset
-	-	-	-	-	-	-	-	-	-	416	411	408	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt discount
747	862	938	899	622	600	572	586	661	1,825	614	456	246	880	163	54	369	171	59	84	0	-	-	-	-	-	-	-	-
Non cash interest expense
150	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of product revenue license fee
355	354	374	212	234	233	167	133	133	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use assets
403	408	379	390	381	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of product revenue license fee
-	-	-	-	-	-	-	-	-	-	-	134	133	133	29	21	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of forgivable loans to registered representatives
-	-	-	-	-	-	-	-	-	-	158	161	201	176	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred clearing credit
-	-	-	-	-	-	-	-	-	-	-53	-52	-52	-13	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expense
3,400	2,765	3,741	3,373	3,309	2,959	4,106	3,152	4,795	1,355	4,312	4,807	2,929	3,336	2,903	3,023	2,866	2,395	8,501	1,925	1,470	1,464	1,484	1,463	1,135	-	-	-	-
Common shares issuable for Opus interest expense
155	0	0	0	281	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of subsidiaries' common shares for research and development expenses
-	-	-	-	-	-	-	-	-	-	-	-	-30	-	-	-	-48	-	0	513	-513	-	-	-	-	-	-	-	-
Change in fair value of subsidiaries' assets and liabilities
-	-	-	-	-	-	-	-	-	-1,237	1,331	-1	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of subsidiaries' assets and liabilities
-	-	-	-	-	-	-	-	-	-1,237	1,331	-1	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issuable for 2017 Subordinated Note Financing interest expense
506	0	10	6	484	0	6	0	489	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Recovery of doubtful accounts
-	-	-	-	-	-	-	-	-	-	18	141	115	47	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	129
Noncash interest expense-related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Contribution of services by stockholder
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Common shares issuable for 2017 Subordinated Note financing interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Common shares issued for 2017 Subordinated Note financing interest expense
-	-	-	-	-	-	-	-	-	-	0	189	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing fees on subsidiaries' Convertible Note, at fair value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of investments
-	-	-	-	-	0	-565	-707	-118	467	270	157	-668	729	-81	-801	-918	-1,610	-1,472	1,622	-215	1,235	-293	0	0	-	-	-	-
Change in fair value of derivative liability
42	-	-	-	0	796	-12	-79	-23	5,523	639	-1,452	-4,342	934	16	0	89	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of partner company convertible note
-	-	-	-	-	411	-84	-140	250	-98	-74	-188	-97	-65	-13	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of partner company convertible note
-	-	-	-	-	411	-84	-140	250	-98	-74	-188	-97	-65	-13	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain on deconsolidation of Caelum
0	45	0	-137	-18,384	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development-licenses acquired, expense
250	4,650	700	200	450	-30	3,706	1	97	770	299	1,830	1,265	695	1,000	2,108	35	1,483	1,294	1,700	6,929	-	-	-	-	-	-	-	-
Asset impairment loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	0	0	723	0	0	0	0
Unrealized (gain) loss on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13	-4	2	-	0	0	0	-	-	-	-
Realized gain on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	0	-	-	-	-
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Accounts receivable
2,271	8,252	2,033	-4,668	2,524	67	110	-2,993	556	2,176	2,246	1,968	-462	1,712	-849	967	0	-	-	-	-	-	-	-	-	-	-	-	-
Receivables from broker-dealers and clearing organizations
-	-	-	-	-	-	-	-	-	-	5,469	-45	-499	4,048	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Forgivable loans receivable
-	-	-	-	-	-	-	-	-	-	30	30	17	84	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Securities owned, at fair value
-	-	-	-	-	-	-	-	-	-	-1,811	2,200	-1,151	179	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
-88	-84	209	103	-49	4	375	77	51	-147	19	95	1	80	23	100	0	-	-	-	-	-	-	-	-	-	-	-	-
Other receivables - related party
888	-378	-607	-279	34	1,681	-361	-169	326	-20	-967	571	-756	245	-1,025	1,256	1,158	87	27	42	0	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
393	14	1,534	-863	-2,483	-1,425	688	-726	1,466	2,585	-1,164	3,225	-635	-593	992	-361	166	414	72	275	-22	93	155	-136	12	231	36	-84	-66
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15,446	1,437	0	14,009	-	-	-	-
Other assets
195	-21	-58	12	949	217	-543	0	343	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current assets held for sale
-	-	-	-	-	-	-4,422	-1,646	-3,383	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncurrent assets held for sale
-	-	-	-	-	-	318	529	427	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current liabilities held for sale
-	-	-	-	-	-	-581	-7,940	-4,040	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
612	5,936	4,805	-4,982	-3,664	5,093	-1,849	-4,753	6,195	6,456	5,916	161	-1,882	31	1,793	3,402	169	1,514	3,455	-933	1,853	517	120	-898	-588	932	-760	1,367	-355
Accounts payable and accrued expenses - related party
-13	0	0	-282	133	-	-	-	-	-	-	24	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses - related party
-	-	-	-	-	-	-	-	-98	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Securities sold, but not yet purchased, at fair value
-	-	-	-	-	-	-	-	-	-	-77	76	-297	298	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest payable
-39	3	17	-33	21	1,191	-530	239	17	154	19	1	2	20	42	-1	0	1	0	0	-2	3	0	0	-84	-7	0	-3	0
Interest payable - related party
39	3	-5	-3	0	-569	0	9	-12	172	171	229	30	66	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Lease liabilities
-54	-425	-227	-362	-351	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
End of term fee associated with Hercules Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-398	0	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	61	-	-	-	0	-	-	-	-
Other long-term liabilities
-47	-46	-46	-47	888	250	-26	229	19	4	-290	6	-4	398	826	1,290	1,832	882	-63	-124	-500	-539	125	-50	0	-	-	-	-
Net cash used in continuing operating activities
-	-	-	-	-	-27,897	-26,988	-16,715	-25,463	-	-	-	-	-	-	-7,382	-11,637	-	-5,243	-6,168	-1,905	-3,527	-2,719	-4,014	-6,074	-7,132	-7,220	-7,802	-7,492
Net cash used in discontinued operating activities
-	-	-	-	-	5,737	2,226	-7,367	-2,381	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-21,892	-25,052	-16,264	-28,320	-25,325	-22,160	-24,762	-24,082	-27,844	-20,861	-25,085	-23,884	-11,475	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows from Investing Activities:
Payment to related parties - CB Pharma Acquisition Corp
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	108	-	0	0	0	-	-	-	-
Deposit for leasehold improvements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Purchase of research and development licenses
-	-	-	-	-	-1	1,000	0	75	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Purchase of long-term investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,675	0	0	250	-	-	-	-
Purchase of research and development licenses
-	-	-	-	-	-	-	-	-	-	300	0	665	-	1,000	2,060	35	-	1,294	1,700	6,929	-	-	-	-	-	-	-	-
Purchase of property and equipment
526	890	500	655	300	339	2,130	3,848	765	-351	545	193	261	614	1,456	2,007	2,293	189	45	49	0	-	-	-	-	-147	-79	264	2
Security deposits refund
-	-	-	-	-	-	-	-	-	0	39	0	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Security deposits refund
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition of business - National
-	-	-	-	-	-	-	-	-	-	0	0	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of intangible assets
1,250	-	-	-	0	-	-	-	-	-	-	-	-	0	0	150	200	0	0	0	1,250	0	0	0	0	-	-	-	-
Purchase of short-term investment (certificates of deposit)
-	-	-	-	-	5,066	12,538	10,000	25,000	12,003	24,050	20,038	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of short-term investment (certificates of deposit)
0	5,000	0	5,044	12,560	10,000	25,000	12,002	24,000	20,089	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deconsolidation of Caelum
0	0	0	0	-1,201	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition of business - National
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Collection on notes receivable
-	-	-	-	-	-	-	-	-	-	20	8	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in Origo Acquisition Corp.
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	175	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by (used in) continuing investing activities
-1,776	310	-3,750	-611	11,059	3,739	9,331	-2,189	-1,840	-	-	-	-	-	-	-4,218	-2,703	-	-21,299	-1,749	-8,287	-22,678	-50	-295	-250	-1	79	-264	-2
Net cash provided by discontinued investing activities
0	0	0	0	13,089	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
-1,776	310	-3,750	-611	24,148	13,522	9,331	-2,189	-1,840	5,777	-24,836	-20,223	-942	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows from Financing Activities:
Payment of Preferred A dividends
1,207	786	601	586	586	586	586	586	586	299	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of treasury stock
70	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of costs related to purchase of treasury stock
2	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of Series A preferred stock
-14,375	-	-	-	0	-1,143	0	-1	1,298	25,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from PCP notes payable-related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of PCP notes payable-related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of PCP notes payable?TSO asset purchase
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of notes payable-related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,896	0	125	481	708	46,389	32,550	11,690
Proceeds from notes payable-related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from issuance of Convertible Preferred Stock Series
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of costs related to the issuance of Series A preferred stock
1,213	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	32	38	867	993	0
Proceeds from at-the-market offering
6,068	4,581	1,979	7,869	6,251	315	2,889	3,841	229	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of cost related to at-the-market offering
188	-	-	-	109	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of cost related to issuance of common stock for at-the-market offering
-	-	-	-	-	17	99	135	6	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of Hercules Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-1	0	0	13,655	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	0	0	27	0	-	-	-	-	0	0	0	216	596	0	0	0	-	-	-	-
Proceeds from partner company's ESPP
169	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from partner company's sale of stock
0	19,557	0	31,624	34,999	0	0	0	23,011	-8,917	10,181	37,949	55,904	28,010	11,082	0	570	45,242	12,575	0	0	-	-	-	-	-	-	-	-
Payment of costs related to partner company's sale of stock
69	1,917	-643	1,897	3,500	0	-11	-1,813	2,167	-9,389	8,527	-2,136	2,998	-	-	-205	205	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from partner company's at-the-market offering
4,997	107	3,421	26,632	366	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of costs related to partner company's at-the-market offering
87	2	135	593	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Assumption of PCP Note related to Asphelia Asset Purchase
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from exercise of partner company's warrants
13	-	-	-	0	0	0	85	96	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs associated with 2017 Subordinated Note Financing
26	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from 2017 Subordinated Note Financing
-	-	-	-	-	-	-	-	-	0	9,388	15,713	3,254	0	0	0	0	0	0	0	10,000	0	0	0	0	-	-	-	-
Payment of costs related to the issuance of Common Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	343
Cashless Exercise Of Warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of debt issuance costs associated with 2017 Subordinated Note Financing
-	-	-	-	-	-	-	149	255	-	-	-	-	-	-	-	-	0	0	0	855	0	0	0	0	-	-	-	0
Proceeds from IDB Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	14,009	0	0	0	0
Proceeds from Opus Credit Facility
-	-	-	-	-	-	-	-	-	0	0	500	2,000	2,000	5,000	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from 2018 Venture Notes
-	-	-	-	-	0	0	0	21,707	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs associated with 2018 Venture Notes
7	8	11	48	67	0	5	49	1,814	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of NSC Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2,792	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	0	0	0	9	0	0	0	0
Proceeds from borrowings under line of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of line of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from partner company's Horizon Notes
0	0	0	0	15,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of debt issuance costs associated with partner company's Horizon Notes
0	0	163	1,000	230	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of partner company's Convertible Notes
-	-	-	-	-	332	0	2,218	1,858	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs associated with IDB Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Transfer of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by continuing financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,521	-2,427	-	11,068	26	9,361	4,372	-1,437	125	-13,215	387	45,522	31,900	11,347
Net cash provided by financing activities
22,753	27,155	5,552	61,894	52,113	-1,692	9,956	2,729	39,655	20,658	17,139	54,424	58,160	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (decrease) increase in cash and cash equivalents, cash deposits with clearing organizations and restricted cash
-	-	-	-	-	-	-	-	-	-	-32,782	10,317	45,743	-	11,201	-10,079	-16,767	-	-15,474	-7,891	-831	-21,833	-4,206	-4,184	-19,539	-6,746	38,381	23,834	3,853
Net (decrease) increase in cash and cash equivalents and restricted cash
-915	2,413	-14,462	32,963	50,936	-10,330	-5,475	-23,542	9,971	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information:
Cash paid for interest
1,609	1,468	1,438	1,438	1,100	681	1,948	1,425	394	196	3	4	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest - related party
-	-	-	-	-	0	0	-572	853	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	81	77	-	0	0	80	171	0	80	534	335	354	351	347
Supplemental disclosure of non-cash financing and investing activities:
Settlement of restricted stock units into common stock
2	0	0	0	2	1	0	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of restricted stock
-	-	-	-	-	-	-	-	-	-	1	0	1	-	0	0	2	-	0	0	1	0	0	0	4	-	-	-	0
Receivable from ATM issuances
-	-	-	-	-	-	-	-	89	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of warrants by subsidiary in conjunction with NSC debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of partner companies'' common shares for settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Issuance of warrants in conjunction with 2017 Subordinated Note Financing
-	-	-	-	-	-	-	-	-	-	-	991	206	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt discount related to Opus Credit Facility
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Debt discount related to Opus Credit Facility
-	-	-	-	-	-	-	-	-	-	0	43	158	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid debt offering costs
8	-	-	-991	1,202	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issuable for license acquired
0	0	0	0	164	-	-	-	-	0	0	0	1,682	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issued for 2017 Subordinated Note Financing interest expense
500	-	-	-	495	-	-	-	500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of partner company warrants in conjunction with Horizon Notes
0	0	0	0	888	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid fixed assets
540	-	-	-	191	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid at-the-market offering cost
6	-	-	55	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid Preferred A offering cost
98	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid research and development licenses acquired
350	-	-	-	250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issued for 2017 Subordinated Note Financing interest expense
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property, plant and equipment included in account payable and accrued liabilities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fixed assets acquired but not paid
-	-	-	-	-	-	-	-1,503	2,321	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inter-company costs related to the issuance of Series A preferred stock
-14,375	-	-	-	0	-1,143	0	-1	1,298	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Business acquisition
-	-	-	-	-	-	-	-	-	-	0	0	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-